Health and Fitness Health and Fitness
Mon, July 2, 2012
[ Mon, Jul 02nd 2012 ] - Market Wire
VICAM's New DON-NIV WB Immunoaffinity Column Sign .. cantly Enhances Laboratory Analysis of Mycotoxins
[ Mon, Jul 02nd 2012 ] - Market Wire
PLC Systems Secures Additional Financing For US Clinical Trials And General Working Capital
[ Mon, Jul 02nd 2012 ] - Market Wire
Avanir Pharmaceuticals Announces Notice Of Allowance Of U.S. Patent Application Covering NUEDEXTA
[ Mon, Jul 02nd 2012 ] - Market Wire
Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device
[ Mon, Jul 02nd 2012 ] - Market Wire
USANA Health Sciences Names Dr. Carsten Smidt As Its Vice President Of Research And Development
[ Mon, Jul 02nd 2012 ] - Market Wire
Equity Research on Perrigo Co. and Auxilium Pharm .. - Drug Related Products Developing and Expanding
[ Mon, Jul 02nd 2012 ] - Market Wire
Onyx Pharmaceuticals Initiates Phase 3 Kyprolisa" .. al vs. Velcade in Patients with Relapsed Multiple
[ Mon, Jul 02nd 2012 ] - Market Wire
Amerigroup Now Serving Members in Washington State
[ Mon, Jul 02nd 2012 ] - Market Wire
Cold-EEZE Announces Launch of NEW Cold-EEZE Cold .. kMelts and achieves Nationwide Product Distributi
[ Mon, Jul 02nd 2012 ] - Market Wire
Cytomedix Announces Extension of Exclusivity Peri .. ompany for Autologel System in Chronic Wound Mark
[ Mon, Jul 02nd 2012 ] - Market Wire
NuPathe Updates Migraine Patch NDA Resubmission Timing
[ Mon, Jul 02nd 2012 ] - Market Wire
The Medicines Company Expects Cangrelor Phase 3 Trial Enrollment Completion in 2012
[ Mon, Jul 02nd 2012 ] - Market Wire
Corcept Therapeutics Commences Public Offering of Common Stock
Sun, July 1, 2012
[ Sun, Jul 01st 2012 ] - Market Wire
New data published on RUCONEST's protective effects after severe blood loss
Fri, June 29, 2012
[ Fri, Jun 29th 2012 ] - Market Wire
Saxena White P.A. Files Securities Fraud Class Action Against Centene Corporation
[ Fri, Jun 29th 2012 ] - Market Wire
Cascade Technologies Appoints Dr. Jerome Swartz t .. ; Highly Accomplished Technology Executive Br
[ Fri, Jun 29th 2012 ] - Market Wire
Faruqi amp;; Faruqi, LLP Encourages Invest .. xcess of $100,000 from Investing in MAKO Surgical
[ Fri, Jun 29th 2012 ] - Market Wire
Faruqi & Faruqi, LLP Encourages Investors Who Suf .. 0,000 from Investing in MAKO Surgical Corporation
[ Fri, Jun 29th 2012 ] - Market Wire
Amerigroup Corporation to Discuss Second Quarter Earnings on August 1
[ Fri, Jun 29th 2012 ] - Market Wire
Digirad and Red Oak Partners Agree to Further Str .. Digirad's Commitment to Governance Best Practices
[ Fri, Jun 29th 2012 ] - Market Wire
Assisted Living Concepts, Inc. Announces Conference Call
[ Fri, Jun 29th 2012 ] - Market Wire
Centene Schedules 2012 Second Quarter Financial Results Conference Call
[ Fri, Jun 29th 2012 ] - Market Wire
Hospira to Host Conference Call for Second-quarter 2012 Results
[ Fri, Jun 29th 2012 ] - Market Wire
Trimel Pharmaceuticals Corporation Announces Terms of $13.25 Million Equity Financing
[ Fri, Jun 29th 2012 ] - Market Wire
Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
[ Fri, Jun 29th 2012 ] - Market Wire
Ohr Pharmaceutical Announces $2.9 Million Financing
[ Fri, Jun 29th 2012 ] - Market Wire
SpectraScience Begins Shipments of WavSTAT4 Optical Biopsy System to PENTAX in Europe
[ Fri, Jun 29th 2012 ] - Market Wire
Sirona Biochem Releases Quarterly Financial Results
[ Fri, Jun 29th 2012 ] - Market Wire
Hamilton Thorne Showcases Two New Products for Fertility Clinics at ESHRE 2012
[ Fri, Jun 29th 2012 ] - Market Wire
Daxor Corporation Announces Filing of Form N-2 an .. ments for the Daxor BVA-100 Blood Volume Analyzer

Daxor Corporation Announces Filing of Form N-2 and Seven Trial Agreements for the Daxor BVA-100 Blood Volume Analyzer


Published on 2012-06-29 05:36:43 - Market Wire
  Print publication without navigation


June 29, 2012 08:30 ET

Daxor Corporation Announces Filing of Form N-2 and Seven Trial Agreements for the Daxor BVA-100 Blood Volume Analyzer

NEW YORK, NY--(Marketwire - Jun 29, 2012) - Daxor Corporation (NYSE MKT: [ DXR ]), a medical instrumentation and biotechnology company, has registered as an investment company. The Company filed a Form N-2 (Registration Statement Under the Investment Company Act of 1940) yesterday, June 28th.

Daxor has begun reporting as an investment company effective January 1, 2012. The Company filed a Form N-Q disclosing its schedule of portfolio holdings as of March 31, 2012.

The Company's next public report will be a Form N-CSR which will be for the six months ended June 30, 2012. This report will be filed with the SEC and sent to shareholders before the end of August 2012.

Since January 1, 2012, the Company has placed seven BVA-100 Blood Volume Analyzers on a trial basis in separate locations within the Continental United States. There are currently 65 Blood Volume Analyzers in service.

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at [ www.Daxor.com ].


Contributing Sources